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Objective: The present study examined whether local administration of the cannabinoid-2 (CB2) receptor
agonist GW405833 could modulate joint nociception in control rat knee joints and in an animal model of
osteoarthritis (OA).
Method: OA was induced in male Wistar rats by intra-articular injection of sodium monoiodo-acetate
with a recovery period of 14 days. Immunohistochemistry was used to evaluate the expression of CB2 and
transient receptor potential vanilloid channel-1 (TRPV1) receptors in the dorsal root ganglion (DRG) and
synovial membrane of sham- and sodium mono-iodoacetate (MIA)-treated animals. Electrophysiological
recordings were made from knee joint primary afferents in response to rotation of the joint both before
and following close intra-arterial injection of different doses of GW405833. The effect of intra-articular
GW405833 on joint pain perception was determined by hindlimb incapacitance. An in vitro neuronal
release assay was used to see if GW405833 caused release of an inﬂammatory neuropeptide (calcitonin
gene-related peptide e CGRP).
Results: CB2 and TRPV1 receptors were co-localized in DRG neurons and synoviocytes in both sham- and
MIA-treated animals. Local application of the GW405833 signiﬁcantly reduced joint afferent ﬁring rate
by up to 31% in control knees. In OA knee joints, however, GW405833 had a pronounced sensitising effect
on joint mechanoreceptors. Co-administration of GW405833 with the CB2 receptor antagonist AM630 or
pre-administration of the TRPV1 ion channel antagonist SB366791 attenuated the sensitising effect of
GW405833. In the pain studies, intra-articular injection of GW405833 into OA knees augmented hin-
dlimb incapacitance, but had no effect on pain behaviour in saline-injected control joints. GW405833
evoked increased CGRP release via a TRPV1 channel-dependent mechanism.
Conclusion: These data indicate that GW405833 reduces the mechanosensitivity of afferent nerve ﬁbres
in control joints but causes nociceptive responses in OA joints. The observed pro-nociceptive effect of
GW405833 appears to involve TRPV1 receptors.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common form of arthritis and is
characterized by extensive remodelling of subchondral bone and
permanent destruction of articular cartilage leading to joint pain.
Currently, no disease modifying drugs are available; therefore,
treatment of OA is primarily restricted to analgesics which often
have limited efﬁcacy and hazardous side-effects. An established: Jason J. McDougall, Depart-
gary, 3330 Hospital Drive NW
ax: 1-403-283-3840.
gall).
s Research Society International. Panimalmodel of OA pain involves the intra-articular injection of the
glycolysis inhibitor sodium mono-iodoacetate (MIA) which
disrupts cartilage metabolism, leading to OA like lesions1e5, nerve
sensitization and joint pain6,7.
A family of agents which have shown great promise for the
treatment of chronic pain are cannabinoids. Cannabinoid agonists
suppress nociceptive transmission and inhibit pain related behav-
iour in different models of arthritis pain7e10. Two cannabinoid
receptors, cannabinoid receptor 1 (CB1 receptor) and cannabinoid
receptor 2 (CB2 receptor), have been cloned and characterized. The
CB1 receptor is present in the central and peripheral nervous
systemwhile the CB2 receptor is predominantly associated with the
immune system11,12.ublished by Elsevier Ltd. All rights reserved.
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speciﬁc cannabinoid agonists have been tested in various pain
models13e18. Current cannabinoid pain therapies are frequently
limited by central nervous system (CNS)-mediated side-effects;
however, selective CB2 receptor agonists have been shown to be
devoid of such effects14,18,19. When applied systemically, the CB2
receptor agonist GW405833 partially reversed the inﬂammation
and hyperalgesia found inmultiple acute inﬂammatorymodels20,21.
In addition to being agonist ligands at cannabinoid receptors,
several cannabinoids are also activators of the transient receptor
potential vanilloid channel-1 (TRPV1)22e25. TRPV1 is expressed on
nociceptive afferent neurones throughout the periphery and has
been demonstrated to play a critical role in the induction of thermal
hyperalgesia in inﬂammatory pain models26e28. Several studies
have shown that the TRPV1 channel is involved in mediating the
anti-nociceptive effect of CB1 agonists22,24,27e29. Thus, certain
cannabinoids may act as dual cannabinoidevanilloid mediators,
particularly under conditions of inﬂammatory hyperalgesia.
This study examined whether local application of the CB2
receptor agonist GW405833 can reduce nociceptive activity of
afferent nerve ﬁbres and pain behaviour in control andMIA-treated
rat knee joints. Since the pro-nociceptive neurotransmitter calci-
tonin gene-related peptide (CGRP) modulates joint mechanonoci-
ception centrally30 and CGRP knockout arthritic mice do not
develop secondary hyperalgesia31, we looked at the release of CGRP
from spinal cord homogenates in order to examine GW405833
activity at native TRPV1 receptors32. Activation of the receptor was
measured in both the basal and stimulated/phosphorylated states
to simulate the normal and diseased conditions respectively.
Methods
Animals
Experiments were performed on 217 male Wistar rats
(250e450 g). The animal handling and surgical procedures out-
lined in this study all adhered to the Canadian Council guidelines
for the care and use of experimental animals which also review
animal ethics.
MIA model of OA
Fifty-three rats were deeply anaesthetised with 2% isoﬂurane in
100% O2 (1 L/min). To induce OA, 50 ml of 3 mg sodium MIA in 0.9%
saline was injected into the joint cavity through the patellar liga-
ment. Animals were allowed to recover for 14 days which has
consistently been shown to cause severe end-stage OA in this
species1,4,5. In a further 42 animals, 50 ml of saline was injected into
the knee joint and this cohort served as a sham control group.
Immunohistochemistry
CB2 and TRPV1 expressions were evaluated in DRGs and syno-
vial membrane from sham-injected (n¼ 4) and MIA-injected
(n¼ 4) male Wistar rats. Animals were anaesthetised and perfused
transcardially with saline followed by 4% paraformaldehyde (PFA)
in phosphate buffered saline (PBS), pH 7.4. DRG (L4eL6) and
synovial membrane were dissected, post-ﬁxed in the 4% PFA/PBS
solution for 3 h at room temperature, and then transferred to a 30%
sucrose/PBS solution and maintained overnight at 4C. Tissue then
was mounted in M1 embedding media (Thermo Shandon, Pitts-
burgh, PA, USA) and stored at 80C. Sections 12e14 mm were cut
from ﬁxed tissue on a cryostat and mounted serially onto Super-
frost Plus microscope slides (Fisher Scientiﬁc, Pittsburgh, PA, USA).
After equilibration to room temperature, the sections were blockedfor endogenous proteins for 1 h with 1 Dako Tris-buffered saline
with Tween 20 wash buffer (Dako, Carpinteria, CA, USA) containing
1% BSA, 0.1% triton X100 and 10% normal serum of the host species
of the second antibody. Sections were incubated overnight at 4C
with a cocktail of primary antibody of rabbit anti-CB2 (gift from
Dr. Ken Mackie, Indiana University, Bloomington, IN) and either
guinea pig anti-TRPV1 for synovium (Neuromics, GP14100, Edina,
MN, USA) or goat anti-TRPV1 for DRG (Santa Cruz, SC-12498, Santa
Cruz, CA, USA), followed by several washes the next morning with
1 wash buffer. Negative staining was conﬁrmed using a blocking
peptide (CB2) or omission of the primary antibody (TRPV1). The
sections then were incubated for 1 h at room temperature with
a cocktail of goat anti-guinea pig Alexa 594 and goat anti-rabbit
Alexa 488 for synovium and a cocktail of donkey anti-goat Alexa
594 and donkey anti-rabbit 488 for the DRG. All secondary anti-
bodies were fromMolecular Probes (Invitrogen, Carlsbad, CA, USA).
Following several washes with 1 wash buffer, the slides were
cover-slipped with ﬂuorescent mounting media and stored in the
dark at 4C for later analysis. Labeling was visualized on a Leica
ﬂuorescence microscope (Bannockburn, IL, USA) equipped with the
appropriate ﬁlter blocks. Merged images were a composite of
single-labeled ﬁles using a feature of Spot software (Diagnostic
Instruments, Sterling Heights, MI, USA). For DRG, cell proﬁles were
outlined and immunohistochemical staining (staining intensity)
was recorded and analyzed using Image Pro Plus software (Media
Cybernetics, Silver Spring, MD, USA).
Surgical procedures
The detailed methods for the surgical procedure have been
described previously7. Rats were deeply anaesthetized with
urethane (25% stock solution; 2 g/kg, i.p.). The left jugular vein was
cannulated so that the muscle relaxant gallamine triethiodide
(50 mg/kg) could be injected to eliminate neural interference arising
from the hindlimb musculature. The right saphenous artery was
cannulated below the knee joint to permit local close intra-arterial
injection of drugs to the knee joint. Rotational torquewas applied to
the knee joint by placing the right hindpaw into a shoe-like holder
which was connected to a force transducer and a torque meter.
Extracellular electrophysiological recording
The technique used for recording afferent activity from articular
nerve ﬁbres in the rat knee joint has been described previously33,34.
The saphenous nerve was isolated in the inguinal region and cut
centrally to prevent the generation of spinally-mediated reﬂexes.
Neural strands were then placed over a platinum electrode to
record single afferent ﬁbre activity. The indifferent electrode was
a silver wire electrode placed in the muscle tissue of the ipsilateral
hindlimb. The receptive ﬁeld of the ﬁbres was identiﬁed by the
elicitation of a response to gentle probing of the knee joint with
a glass rod. The mechanical threshold of each recorded joint
afferent was determined by a gradual increase of the torque applied
to the joint until the ﬁbre starts eliciting action potentials. The
mechanosensitivity of articular afferents was measured in response
to outward non-noxious rotation and noxious hyper-rotation of the
knee joint. Since no differences were observed between the two
movements in respect to the effect of the applied drugs, the data for
both rotation movements were pooled for statistical analysis. The
amount of force applied during the joint rotation ranged between
15 and 25 mNm for the non-noxious movement and between 35
and 45 mNm for the noxious movement. To establish a control
baseline level of activity for each ﬁbre, three movement cycles of
the knee to discrete torque levels were performed at the beginning
of the experiment and the mean afferent ﬁring rate was taken as
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baseline were calculated after close intra-arterial injection of either
vehicle or GW405833 (1012 mol; 1010 mol; 108 mol; 100 ml
bolus). In a separate group of animals the CB2 receptor antagonist
AM630 (108 mol; 100 ml bolus) or the TRPV1 receptor antagonist
SB366791 (500 mg/kg i.p.) was administered 30 min prior to the
GW405833 to conﬁrm cannabinoid and/or TRPV1 receptor
involvement in joint mechanosensitivity. Doses of GW405833 were
chosen based on our previous experience with cannabinoid
agonists7. The conduction velocity of the nerve ﬁbres was deter-
mined by electrically stimulating their receptive ﬁeld with a pair of
bipolar, silver wire electrodes. Afferents with conduction velocities
below 2 m/s were classiﬁed as unmyelinated type IV ﬁbres,
whereas afferents with conduction velocities above 2 m/s were
classiﬁed as thinly myelinated type III ﬁbres.
Weight-bearing assessment
On three consecutive days prior to behavioural testing, rats were
regularly handled and gradually habituated to the test equipment.
Hindlimb weight bearing was determined using an incapacitance
tester (Linton, Norfolk, UK) consisting of a dual channel weight
averager. The force exerted by each hindlimb (measured in grams)
was averaged over a 5 s period. Each data point is the mean of three
readings. The percent weight distribution onto the treated (ipsi-
lateral) hindlimb was calculated. For the MIA animals, weight
distribution was measured between treated (intra-articular injec-
tion of GW405833: 106 mol; 100 ml bolus) and contralateral non-
treated hindlimbs. For the antagonist studies, either the TRPV1
antagonists SB366791 (500 mg/kg i.p.) or the CB2 receptor antago-
nist AM630 (108 mol; l00 ml bolus) was injected 30 min prior to
administration of GW405833.
CGRP release assay
Adult male rats were sacriﬁced by exposure to CO2 followed by
cervical dislocation. The lumbar portion (L1eL6) of the spinal cord
was dissected out and homogenised in 15 ml of ice-cold Krebs
buffer per cord. The homogenate was diluted to 5 mg/ml and plated
into a 96-well ﬁlter plate (100 ml/well). Phosphorylation of the
TRPV1 receptor was achieved by activation of protein kinase C
through addition of a low concentration (10 nM) of phorbol 12,13-
dibutyrate (PDBu). Buffer was removed by vacuum ﬁltration and
buffer with or without PDBu and/or antagonist was added (100 ml/
well) and the plate incubated at 37C for 10 min. Agonists with or
without PDBu and/or antagonist were added (100 ml/well) and the
plate incubated for a further 10 min at 37C. Buffer was then
transferred into the immunoplate (SpiBio, Montigny Le Bretonneux,
France). Anti-CGRP tracer was added to all wells (100 ml/well) and
the plate covered with plastic ﬁlm and incubated at 4C for
16e20 h. After the incubation period the plate was washed with
wash buffer (300 ml/well) and Ellman’s reagent added (200 ml/well).
The plate was left at room temperature to develop for 45 min and
absorbance read at 405 nm. Data were expressed as a percentage of
300 nM capsaicin control and curves were ﬁtted using the 4
parameter Hill equation.
Drugs and reagents
Sodium MIA, GW405833, AM630, SB366791 were obtained
from Tocris Bioscience (Missouri, USA; Bristol, UK); gallamine
triethiodide, PDBu, capsaicin, DMSO, cremophor and urethane
were obtained from SigmaeAldrich (Ontario, Canada; Poole, UK).
All reagents were dissolved in vehicle solution (2% DMSO, 1% cre-
mophor, 0.9% saline) and aliquots of the drug were kept frozen(20C) in Eppendorf vials until required. The pH of all solutions
was determined to exclude acidity as a sensitising factor on afferent
nerve ﬁbres. All solutions were found to have a neutral pH (pH 7.4)
before injection. For the CGRP release assays, drugs were dissolved
at 10 mM in 100% DMSO and then diluted in Krebs buffer. Gall-
amine triethiodide was made fresh on the day of experimentation
and dissolved in 0.9% saline.
Statistics
All datawere normally distributed and expressed as means with
95% conﬁdence interval (CI e lower, upper limits) for “n” obser-
vations. The effect of administered drugs between animal groups
was analyzed by either one- or two-way analysis of variance
(ANOVA) with Bonferroni’s multiple comparisons post-test and an
unpaired Student’s t test. The time course and dose-dependency of
GW405833 were tested by one-way ANOVA with individual points
being compared to control using a one-sample t test. Themaximum
response produced by GW405833 maximal efﬁcacy (Emax) was
calculated from doseeresponse curves. All differences were
considered statistically signiﬁcant at a P value less than 0.05.
Results
Colocalization of CB2 and TRPV1 receptors in DRG and synovium of
control and MIA-treated animals
Consistent with previous results, CB2 antibody staining was
observed in small, medium and large diameter neurons in the DRG
of both sham- and MIA-treated animals [Fig. 1(A); Supplementary
Fig. 1(A)]; whereas TRPV1 antibody labeling was primarily
restricted to small- and medium-sided cells in both groups of
animals [Fig. 1(B); Supplementary Fig. 1(B)]. In addition, TRPV1
staining was evident in approximately 25% of CB2-positively
stained cells in DRGs from saline- and MIA-treated rats [Fig. 1(C);
Supplementary Fig. 1(C)].
In sham- andMIA-treated animals, both CB2 and TRPV1 antibody
labeling was found in cells of the synovial membrane [Fig. 1(D) and
(E); Supplementary Fig.1(D) and (E)]. Examination of the individual
antibody-labeled tissue sections and merged images indicated that
there were many instances of synovial cells doubleelabeled with
CB2 and TRPV1 antibodies [Fig.1(F); Supplementary Fig.1(F)].While
a quantitative assessment was not conducted in these studies, there
were no apparent differences in the pattern or level of expression of
CB2 and TRPV1 receptors in synovium or DRG fromMIA- and sham-
treated knee joints at 14 days after injection.
Neuronal characteristics
Between 1e3 afferent ﬁbres were examined per animal such
that a total of 154 units (77 units in control knee joints; 77 units in
MIA-treated knee joints) were recorded in this study. The electro-
physiological characteristics of these ﬁbres are summarized in
Table I. The basal ﬁring rate of afferents in the control joint was
30.8 (CI: 27.5e34.0) during non-noxious movement and 76.5
(CI: 71.6e81.4) during noxious movement. The basal ﬁring rate of
afferents in the MIA joint was 49.0 (CI: 45.7e52.2) during non-
noxious movement and 100.0 (CI: 95.2e104.8) during noxious
movement. Compared to saline-injected control joints, the average
ﬁring rate of afferents in the MIA-treated knee joint was signiﬁ-
cantly higher during both joint rotations (P< 0.0001 unpaired
Student’s t test). All units tested could be activated by local intra-
arterial injection of KCl (0.4 mM, 0.1 ml) at the end of the
experiment conﬁrming that administered reagents reached
mechanosensory nerve endings throughout the experiment.
Fig. 1. Colocalization of CB2 and TRPV1 antibodies in sham-injected control rat DRG cells (AeC) and synovial membrane (DeF). CB2 (green: A) and TRPV1 (red: B) antibody staining
is evident in the lumbar DRG cells. CB2 staining is evident in small, medium and large diameter DGR cells, whereas TRPV1 expression is primarily in small- and medium-sized cells.
Merged images (C) indicate colocalization of CB2 and TRPV1 in small to medium-sized cells (open arrows). Examples of large diameter DRG neurons positively labeled with CB2 only
are also shown (arrow heads). Scale bars¼ 100 mm. In the synovial membrane, CB2 (green: D) and TRPV1 (red: E) antibody staining is evident. Merged images (F) indicate
colocalization of CB2 and TRPV1 antibody labeling in synoviocytes (open arrows). Scale bars¼ 50 mm.
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With rotation of control knee joints, injection of GW405833
induced a signiﬁcant suppression ofmechanosensory nerve activity.
A specimen recording showing the inhibitoryeffectofGW405833on
afferentﬁring rate is shown inFig. 2(A). Applicationof vehiclehadno
signiﬁcant effect on mechanosensitivity. The desensitizing effect of
GW405833 was found to be dose-dependent across the dose range
1012e108 mol, [P< 0.0001; one-way ANOVA; Fig. 2(B)]. The EmaxTable I
Proportion and range of electrophysiological characteristics of thinly myelinated
type III and unmyelinated type IV ﬁbres recorded in control and osteoarthritis (OA)
knee joints. MT¼mechanical threshold; ET¼electrical threshold; CV¼ conduction
velocity
MT (mNm) ET (V) CV (m/s) % of ﬁbres
Control joints Type III 5e34 6.5e9 2.6e7.4 39
Type IV 7e45 5.5e10.5 0.4e2.4 61
OA joints Type III 3e16 6e10 2.9e23.4 28
Type IV 3e22 6.5e12 0.6e2.4 72of GW405833 was 26.5% (CI: 33.3 to 19.7). Compared to the
vehicle, the desensitizing effect of GW405833 was statistically
signiﬁcant [P< 0.0001 two-way ANOVA; Fig. 2(B); n¼ 22e27].
Effect of GW405833 in MIA knee joints
In MIA joints, GW405833 caused a signiﬁcant sensitization of
recorded ﬁbres while application of vehicle had no signiﬁcant effect
on joint mechanosensitivity. A specimen recording showing the
excitatory effect of GW405833 on afferent nerve activity in MIA
joints is shown in Fig. 3(A). The sensitising effect of GW405833 was
found to be dose-dependent across the dose range 1012e108 mol
[P< 0.0001; one-way ANOVA; Fig. 3(B)] with an Emax of 34.9%
(CI: 24.7e45.1). Compared to vehicle, this sensitising effect was
statistically signiﬁcant (two-way ANOVA P< 0.0001; n¼ 24e28).
Response characteristics of type III and type IV ﬁbres
In a subgroup of recorded ﬁbres, the response properties of type
III vs type IV afferents were compared. No differences inmechanical
Fig. 2. Effect of GW405833 on control knee joints. (A) Specimen recording of a single
unit during rotation of a control knee joint before and after close intra-arterial
application of GW405833. GW405833 signiﬁcantly reduced the ﬁring rate of joint
afferent nerve ﬁbres. (B) The effect of GW405833 on knee joint afferent nerve
mechanosensitivity in response to rotation of saline-injected knee joints. The desen-
sitizing effect of GW405833 was dose-dependent and signiﬁcantly different from the
effect of vehicle control treatment [P< 0.0001 by two-way ANOVA (n¼ 22e27 ﬁbres)].
Values are the mean of all time points with 95% CIs.
Table II
Response characteristics of type III and type IV ﬁbres after GW405833 application. In
control joints the desensitizing effect of GW405833 was signiﬁcantly higher in type
III ﬁbres compared to type IV ﬁbres. InMIA joints the sensitising effect wasmediated
via type IV ﬁbres. Differences between type III and type IV ﬁbres were assessed using
an unpaired Student’s t test. [Data are means with 95% CIs (lower limit, upper limit)]
% change ﬁring rate N P value
Control joints Type III 61.6 (79.9, 43.3) 30
Type IV 29.5 (42.61, 16.37) 67 (0.005)
MIA joints Type III 2.3 (8.4, 13.1) 40
Type IV 27.4 (9.0, 45.4) 85 (0.007)
N. Schuelert et al. / Osteoarthritis and Cartilage 18 (2010) 1536e15431540threshold, voltage threshold or baseline ﬁring frequency were
found; however, the inhibitory effect of GW405833 in control
animals was mediated mainly by activation of type III ﬁbres since
the inhibitory effect of type IV ﬁbres is comparatively smaller
(unpaired Student’s t test; P¼ 0.005; Table II). The pro-nociceptive
effect of GW405833 in MIA animals was mediated by activation of
type IV ﬁbres since type III ﬁbres were not sensitized by GW405833
(unpaired Student’s t test; P¼ 0.007; Table II).Fig. 3. Effect of GW405833 on osteoarthritis (OA) joints. (A) Specimen recording of
a single unit during rotation of an OA knee joint before and after close intra-arterial
application of GW405833. GW405833 signiﬁcantly sensitized the ﬁring rate of joint
afferent nerve ﬁbres. (B) The effect of GW405833 on knee joint afferent nerve
mechanosensitivity in response to rotation of OA knee joints. The sensitising effect of
GW405833 was dose-dependent and signiﬁcantly different from the effect of vehicle
control treatment [P< 0.0001 by two-way ANOVA (n¼ 24e28 ﬁbres)]. Values are the
mean of all time points with 95% CIs.Effect of selective CB2 receptor antagonism on GW405833 responses
in control knee joints
Co-administration of the selective CB2 receptor antagonist
AM630 reduced the desensitizing effect of the highest dose of
GW405833 [P< 0.0001 one-way ANOVAwith Bonferroni’s multiple
comparison test; n¼ 20; Fig. 4(A)]. AM630 given alone had no
signiﬁcant effect on afferent ﬁring frequency in control knees.
Effect of selective CB2 and TRPV1 receptor antagonism on
GW405833 responses in MIA knee joints
The CB2 receptor antagonist AM630 signiﬁcantly blocked the
sensitising effect of GW405833 [P< 0.0001; one-way ANOVA with
Bonferroni’s multiple comparison test; n¼ 17; Fig. 5(B)]. Pre-
administration of the TRPV1 receptor antagonist SB366791 before
GW405833 also inhibited the sensitising effect of the cannabinoid
during joint rotation [P< 0.0001; one-way ANOVA with Bonferro-
ni’s multiple comparison test; n¼ 26; Fig. 4(B)]. AM630 and
SB366791 given alone had no signiﬁcant effect on afferent ﬁring
frequency in MIA knees.Fig. 4. (A) Effect of co-administration of the CB2 receptor antagonist AM630 with
GW405833 (108 mol) on control (saline-injected) knee joints. The CB2 antagonist
AM630 signiﬁcantly reduced the desensitizing effect of GW405833; one-way ANOVA
with Bonferroni’s multiple comparison test. (B) In the OA joint GW405833 causes
signiﬁcant sensitization compared to the vehicle. This GW405833-mediated sensiti-
zation was blocked by co-administration of AM630 or by pre-administration of the
TRPV1 receptor antagonist SB366791; one-way ANOVA with Bonferroni’ s multiple
comparison test. When administered alone, AM630 or SB366791 had no signiﬁcant
effect on joint mechanosensitivity. Values are the mean of all time points with 95% CIs
of 12e28 ﬁbres.
Fig. 5. Effect of intra-articular injection of GW405833 (106 mol) on hindpaw weight
distribution in control and OA joints, compared to vehicle injection. In control joints,
GW405833 had no signiﬁcant effect on weight distribution compared to naive rats. In
OA rats, following GW405833 injection, body weight was redistributed onto the non-
injected contralateral hindlimb while co-administration of the CB2 receptor antagonist
AM630 or pre-administration of the TRPV1 receptor antagonist SB366791 attenuated
this GW405833 induced weight-bearing deﬁcit. The algesic effect of GW405833 was
maximal 60 min after injection. Bonferroni’s multiple comparison test; n¼ 8 animals/
group. Data are means with 95% CIs.
Fig. 6. Concentrationeresponse curves for the effect of GW405833 on CGRP release
from adult rat spinal cord. GW405833 assayed alone under basal (open squares)
conditions of the TRPV1 channel no CGRP release was observed. After phosphorylation
of the TRPV1 channel (solid triangles) CGRP release was signiﬁcantly increased (two-
way ANOVA P< 0.001). Each data point represents mean CGRP release with 95% CIs
expressed as a percent of capsaicin and buffer controls. n¼ 3.
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MIA knee joints
The induction of OA caused a signiﬁcant reduction in the amount
ofweight being borne on the ipsilateral hindlimb compared to naïve
rats (P¼ 0.001; one-way ANOVA with Bonferroni’s multiple
comparison test; n¼ 8; Fig. 5).While naive rats distribute their body
weight evenly between the twohindlimbs, in theMIA rat theweight
placed on the ipsilateral hindlimb was reduced to about 30%. Intra-
articular injection of GW405833 (106 mol) into the MIA-treated
joint caused a further shift inweight distribution such that only 20%
of the animal’s body weight was being placed on the ipsilateral
hindlimb. The shift in weight distribution reached a maximal level
of incapacitance at the 60 min time point (P< 0.001; one-way
ANOVA with Bonferroni’s multiple comparison test; n¼ 8; Fig. 5).
This observation indicates that GW405833 caused an enhancedpain
response in the MIA joint. Injection of the vehicle had no effect on
weight distribution. In saline-injected control rat knees, intra-
articular injection of GW405833 had no signiﬁcant effect on hin-
dlimb weight distribution (P¼ 0.67 one-way ANOVA; n¼ 6; Fig. 5).
Effect of CB2 and TRPV1 blockade on hindlimb weight distribution
Intra-articular co-administration of the CB2 antagonist AM630
(108 mol) completely blocked the GW405833-mediated pain
response at the 60 min time point (P< 0.001; one-way ANOVAwith
Bonferroni’s multiple comparison test; n¼ 8; Fig. 5). Furthermore,
intraperitoneal injection of the TRPV1 channel antagonist SB366791
prior to intra-articular injection of GW405833 blocked the pain
response to the CB2 agonist (P< 0.001; one-way ANOVA with Bon-
ferroni’smultiple comparison test; n¼ 8). Administration of AM630
or SB366791by itself hadno signiﬁcant effect on joint incapacitance,
compared to vehicle. These behavioural data are consistentwith the
electrophysiological results, conﬁrming that GW405833 causes
a painful response in the MIA joint and that both the CB2 receptor
and the TRPV1 channel are involved in mediating this effect.
In vitro CGRP release e effect of phosphorylation of the TRPV1
receptor
The effect of GW405833 was assessed in vitro under both basal
(non-phosphorylated) and stimulated (phosphorylated) conditions.With the TRPV1 receptor in its non-phosphorylated state, GW405833
had no effect on CGRP release up to a concentration of 30 mM (Fig. 6).
However, with TRPV1 in the phosphorylated state, GW405833
evoked a signiﬁcant release of CGRPwith an EC50 of 9 mMand Emax of
60% (compared to a maximally effective concentration of 0.3 mM
capsaicin). These data suggest that under phosphorylated conditions
GW405833 can act as an agonist at the TRPV1 receptor.Discussion
Several studies conﬁrm the presence of functionally active CB2
receptors on immunocytes, primary afferent nerves, dorsal root
ganglia and in the spinal cord35e37. Recently, CB2 receptorexpression
has been demonstrated in the synovium of OA patients, supporting
a potential role for CB2-selective ligands in the treatment of arthritis
pain36e38. In the present study, wediscovered that CB2 receptors are
present in the knee joints of rats and that local application of the CB2
receptor agonist GW405833 inhibited nociceptive responses in non-
arthritic knee joints. In the MIA joint, however, GW405833 was no
longer anti-nociceptive, but surprisingly led to sensitization of joint
mechanosensitive nerve ﬁbres. These electrophysiological ﬁndings
were corroborated in a behavioural test of joint painwhich showed
an algesic effect of GW405833 after induction of OA whereas the
drug had no effect on weight bearing in control animals. The para-
doxical ﬁnding that GW405833 is anti-nociceptive in control joints
but pro-nociceptive inMIA knees indicates that themodulatory role
of this particular cannabinoid in pain transmission is dictated by the
pathophysiological status of the organ. Similar observations have
been reported in other studies where the CB2 receptor agonist
JWH133 produced an increase in synovial blood ﬂow when applied
locally in normal knee joints but failed to elicit any signiﬁcant
vasomotor changes in inﬂamed knee joints39. The algesic effect of
GW405833 highlighted here is in contrast to other studies showing
an analgesic effect of GW405833 in models of acute inﬂammatory
pain16,21,40e42. It should be noted, however, that in the aforemen-
tioned studies GW405833 was administered systemically in very
high doses and could therefore be having spinal or even supraspinal
sites of action43.
The mechanisms responsible for the reported anti-nociceptive
effects of CB2 agonists are still unknown. In the present study, it is
unlikely that GW405833 is inhibitingmechanosensitivity in normal
joints by activating CB2 receptors on immunocytes thereby
decreasing the release of pro-inﬂammatory mediators since there
are negligible amounts of circulating inﬂammatory cells under
control conditions. It is more likely that the anti-nociceptive effect
of GW405833 reported here represents a direct inhibition of
N. Schuelert et al. / Osteoarthritis and Cartilage 18 (2010) 1536e15431542mechanotransduction in joint primary afferent nerve ﬁbres. Closer
analysis of the relative contribution of different mechanosensitive
nerve ﬁbre subtypes to this phenomenon revealed that type III and
type IV afferents produced a differential response to GW405833.
The observed reduced mechanosensitivity in control joints was
mainly mediated via thinly myelinated type III afferents, whereas
the pro-nociceptive effect of GW405833 in MIA joint was mediated
mainly by type IV afferents. Interestingly, these electrophysiological
ﬁndings correspond with our histological data which showed that
CB2 receptors on large and medium-sized neurones (type III ﬁbres)
occur in isolation whereas CB2 receptors on small sized neurones
(type IV ﬁbres) often co-localize with the pro-nociceptive TRPV1
channel. It has been shown that unmyelinated type IV ﬁbres orig-
inate from small diameter somata and myelinated type III ﬁbres
originate frommedium and large diameter somata44. This ﬁnding is
similar to a previous study showing TRPV1 and CB2 receptor co-
localisation in a subpopulation of human sensory neurones25. Thus
in MIA joints, GW405833 may promote joint pain by interacting
with TRPV1 channels on type IV joint afferents. Indeed in this study,
pre-treatment of MIA joints with the TRPV1 antagonist SB366791
blocked the pro-nociceptive and hyperalgesic effects of GW405833.
Evidence elsewhere found that CB2 receptor activation can modu-
late TRPV1 sensitivity25 and that the TRPV1 channel is essential for
the functional activity of CB2 receptor agonists in modulating
synovial blood ﬂow39.
An additional explanation as to why GW405833 reduced
mechanosensitivity in control joints but increased nociceptive
responses when administered to MIA joints may be related to
whether the TRPV1 channel exists in its phosphorylated (sensi-
tized) or dephosphorylated (desensitized) state45,46. In an in vitro
assay, we found that GW405833 caused the release of the pro-
nociceptive neuropeptide CGRP from spinal cord neurones but only
when neuronal TRPV1 receptors were in the phosphorylated state.
Thus, GW405833 may be acting as a weak partial agonist at the
phosphorylated TRPV1 receptor leading to the secondary release of
CGRP which further sensitises joint nociceptors causing pain.
Inﬂammation-induced phosphorylation of TRPV147,48 as well as an
up-regulation of the channel49 could increase the probability of
GW405833 binding to TRPV1 in MIA animals such that the pro-
nociceptive, TRPV1-mediated actions of GW405833 in MIA knees
supersede its anti-nociceptive CB2 receptor-mediated effects as
seen in normal joints.Conclusion
In this study it was found that local administration of the CB2
receptor agonist GW405833 signiﬁcantly suppressed joint noci-
ceptive transmission in normal joints by reducing primary afferent
nerve activity. Conversely in MIA joints, GW405833 appears to bind
to sensitized TRPV1 receptors on type IV joint afferents leading to
the secondary release of CGRP which further sensitises joint
afferents causing hyperalgesia. Whether this process holds true for
other CB2 receptor agonists requires additional investigation.Author contributions
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